Deciphex plans to expand further in the UK, Canada and the Middle East, while launching its online clinical service in the US. Irish pathology and AI start-up Deciphex has today (19 May) announced the closing of an $11.5m Series B funding round, to boost growth and launch its clinical service in the US. The round was led by ACT Venture Capital, with Charles River Laboratories, Novartis, IRRUS Investments, Nextsteps Capital, HBAN Medtech Syndicate and other current investors also participating. Founded in 2017, Deciphex has offices in Dublin, the UK and the US.